- US12617754utility2026Process for Synthesizing Lipids0 cites
- US12617850utility2026Treatment of Pd-l1-positive Melanoma Using an Anti-pd-1 Antibody0 cites
- US12608626utility2026Plug-and-analyze Framework for Knowledge Base Construction0 cites
- US12590154utility2026Cancer Immunotherapy by Disrupting PD-1/PD-L1 Signaling0 cites
- US12590153utility2026Treatment of Pd-l1-negative Melanoma Using an Anti-pd-1 Antibody and an Anti-ctla-4 Antibody0 cites
- US12577206utility2026Pyrazolone Formyl Peptide 2 Receptor Agonists0 cites
- US12577214utility2026Polymorphs of Bis(fluoroalkyl)-1,4-benzodiazepinone Compounds and Uses Thereof0 cites
- US12570671utility2026Substituted Oxoisoindoline Compounds for the Treatment of Cancer0 cites
- US12570659utility2026Bicyclic Heteroaryl Compounds Useful as IRAK4 Inhibitors0 cites
- US12570609utility2026Tricyclic Sulfones as ROR Gamma Modulators0 cites
- US12565483utility2026Oxopyrrolidine Urea FPR2 Agonists0 cites
- US12565528utility2026LAG-3 Antagonist Therapy for Lung Cancer0 cites
- US12534511utility2026Serum Albumin-binding Fibronectin Type III Domains0 cites
- US12528865utility2026Treatment of Lung Cancer Using a Combination of an Anti-pd-1 Antibody and an Anti-ctla-4 Antibody1 cite
- US12529165utility2026Stabilized Fibronectin Based Scaffold Molecules0 cites
- US12527783utility2026Salts/cocrystals of (r)-n-(4-chlorophenyl-2-((1s,4s)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide0 cites
Page 1 of 13Next →